Ausgabe 11/2009
Inhalt (9 Artikel)
Current Opinion
Do Biological Medicinal Products Pose a Risk to the Environment?
Thomas C. Kühler, Mikael Andersson, Gunnar Carlin, Ann Johnsson, Lennart Åkerblom
Review Article
A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours
Dominik Wolf, Holger Rumpold
Review Article
Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies
Silvio Caccia, Silvio Garattini, Luca Pasina, Alessandro Nobili
Original Research Article
Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials
Winfried Rief, Yvonne Nestoriuc, Anna von Lilienfeld-Toal, Imis Dogan, Franziska Schreiber, Stefan G. Hofmann, Arthur J. Barsky, Jerry Avorn
Original Research Article
Risk Management Policy and Black-Box Warnings
Daniel M. Cook, Rama K. Gurugubelli, Lisa A. Bero
Original Research Article
Consumer Reporting of Adverse Drug Reactions
Lise Aagaard, Lars Hougaard Nielsen, Ebba Holme Hansen
Original Research Article
Effectiveness of Safety Warnings in Atypical Antipsychotic Drugs
Gabriel Sanfélix-Gimeno, Pedro Cervera-Casino, Salvador Peiró, Beatriz González López-Valcarcel, Amparo Blázquez, Teresa Barbera
Original Research Article
Mortality Associated with Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment
Suzanne McCarthy, Noel Cranswick, Laura Potts, Eric Taylor, Ian C. K. Wong
Commentary
Attention-Deficit Hyperactivity Disorder (ADHD) Treatment and Sudden Death
Frank M.C. Besag